Financing News
Recently, Eieling Technology completed an angel round of financing of nearly 10 million yuan. Eieling Technology has survived the capital winter by relying on its exclusive patented innovative technology of instantaneous elastic imaging wireless ultrasound under real-time guidance of B-ultrasound. This round of financing was jointly invested by leading supply chain companies in the industry and multiple partners in the global market.
Eieling Technology was established in Hong Kong Science Park in 2018. As a representative enterprise of the Department of Biomedical Engineering of the Hong Kong Polytechnic University, it has established a basic research and development base and an overseas marketing center in Hong Kong. In the past two years, in order to accelerate the expansion of the domestic market, it has established an engineering research and development center and a production base in Shenzhen, making full use of Shenzhen’s scientific and technological innovation atmosphere and perfect industrial chain to improve production and R&D efficiency. At the same time, it has established a domestic headquarters and a domestic marketing center in Shanghai, which are mainly responsible for marketing and promotion in the domestic market, and provide domestic customers with faster and higher-quality services. Eieling Technology’s deployment plan across the two sides of the Taiwan Strait and Hong Kong has laid the foundation for the company’s global development.
Eieling Technology focuses on providing portable ultrasound solutions in the field of chronic liver disease. Its flagship product Liverscan C is equipped with patented B-type ultrasound real-time image guidance function. Its unique wireless design can provide flexible customized solutions for different scenarios. In addition to the traditional application in hospital infection and gastroenterology departments, it can also be used in hepatobiliary surgery, endocrinology, cardiology, surgery and emergency scenarios, covering chronic disease management centers, community clinics, insurance/pharmaceutical companies, operators, chain physical examination institutions, pharmacies, real estate, sports and fitness institutions, as well as grassroots liver cancer early screening, free clinics organized by foundations, rural revitalization physical examinations, and liver disease screening in the mountains and villages. Conservative estimates for the upstream and downstream industry chains can give rise to a market size of hundreds of billions.
This round of financing represents the capital market’s recognition of Eieling Technology’s development prospects and marks that Eieling Technology’s development has reached a new level. With the support of the capital market, Eieling Technology will obtain more resources and opportunities to provide global customers with better products and services.
Thanks to investors for their trust and support, Eieling Technology will continue to deepen its research and development in the field of chronic liver disease, continue to develop the vision of “making high-end technology accessible to the public”, create more value for customers, and make greater contributions to the development of the global medical technology industry.
We welcome continued attention from more investment institutions and market partners in the industry!